Literature DB >> 18533240

The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer.

Alexandra Giatromanolaki1, Gaynor J Bates, Michael I Koukourakis, Efthimios Sivridis, Kevin C Gatter, Adrian L Harris, Alison H Banham.   

Abstract

OBJECTIVES: CD4(+)CD25(+) regulatory T-cells (Tregs), that express the transcription factor FOXP3, suppress effector T-cell populations and can enable tumour cells to evade the host immune response. In this study, we investigated the numbers of FOXP3(+) Tregs in the normal and malignat endometrium and examined potential links with tumor angiogenesis.
METHODS: Paraffin-embedded tissues from 79 patients with stage I endometrial adenocarcinoma and 12 samples from normal endometrium were analyzed using immunohistochemistry for the detection of FOXP3(+) lymphocytes. The presence of FOXP3(+) lymphocytic infiltration was correlated with the tumor vascular density, the hypoxia inducible factors HIF-1alpha and HIF-2alpha, VEGF, estrogen and progesterone receptor expression. Survival analysis was also performed.
RESULTS: In normal endometrium, FOXP3 was expressed by stroma infiltrating lymphocytes, with a mean number 8 (range 5-11) lymphocytes per x100 optical field. In tumors, 55/79 (69.6%) cases showed little FOXP3(+) lymphocytic infiltration (0-2 per x100 optical field). In the remaining 24/79 (30.4%) cases that were scored as positive the mean score ranged from 3-8 (median 5). Low numbers of FOXP3(+) lymphocytes significantly correlated with tumoral ER negativity and low vascular density. Survival analysis showed no significant impact of FOXP3 lymphocytic infiltration, although there was a trend towards worse prognosis.
CONCLUSIONS: The correlation between the presence of FOXP3(+) Tregs and high vessel density in endometrial adenocarcinomas suggests a link between immunity, intratumoral angiogenesis and poor prognosis. However, further studies are required as significantly fewer Tregs were detected in the tumor microenvironment compared to normal endometrium.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18533240     DOI: 10.1016/j.ygyno.2008.04.021

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  27 in total

1.  T cell-inflamed phenotype and increased Foxp3 expression in infiltrating T-cells of mismatch-repair deficient endometrial cancers.

Authors:  Shiho Asaka; Ting-Tai Yen; Tian-Li Wang; Ie-Ming Shih; Stephanie Gaillard
Journal:  Mod Pathol       Date:  2018-11-06       Impact factor: 7.842

2.  T cells, mast cells and microvascular density in diffuse large B cell lymphoma.

Authors:  Christian Marinaccio; Giuseppe Ingravallo; Francesco Gaudio; Tommasina Perrone; Simona Ruggieri; Giuseppina Opinto; Beatrice Nico; Eugenio Maiorano; Giorgina Specchia; Domenico Ribatti
Journal:  Clin Exp Med       Date:  2015-05-10       Impact factor: 3.984

3.  The parallel lives of angiogenesis and immunosuppression: cancer and other tales.

Authors:  Gregory T Motz; George Coukos
Journal:  Nat Rev Immunol       Date:  2011-09-23       Impact factor: 53.106

4.  Dendritic cell immunotherapy in uterine cancer.

Authors:  An Coosemans; Sandra Tuyaerts; Anke Vanderstraeten; Ignace Vergote; Frédéric Amant; Stefaan W Van Gool
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 5.  T-regulatory cells: key players in tumor immune escape and angiogenesis.

Authors:  Andrea Facciabene; Gregory T Motz; George Coukos
Journal:  Cancer Res       Date:  2012-05-01       Impact factor: 12.701

6.  Cytotoxic T-Cells in Peripheral Blood in Women with Endometriosis.

Authors:  N Slabe; H Meden-Vrtovec; I Verdenik; R Kosir-Pogacnik; A Ihan
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-10       Impact factor: 2.915

Review 7.  Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.

Authors:  Shernan G Holtan; Douglas J Creedon; Paul Haluska; Svetomir N Markovic
Journal:  Mayo Clin Proc       Date:  2009-11       Impact factor: 7.616

Review 8.  Immunotherapy in endometrial cancer: rationale, practice and perspectives.

Authors:  Wenyu Cao; Xinyue Ma; Jean Victoria Fischer; Chenggong Sun; Beihua Kong; Qing Zhang
Journal:  Biomark Res       Date:  2021-06-16

9.  Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance.

Authors:  C Tanchot; M Terme; H Pere; T Tran; N Benhamouda; M Strioga; C Banissi; L Galluzzi; G Kroemer; E Tartour
Journal:  Cancer Microenviron       Date:  2012-10-27

Review 10.  Immunotherapy: New Strategies for the Treatment of Gynecologic Malignancies.

Authors:  Ariel Bulua Bourla; Dmitriy Zamarin
Journal:  Oncology (Williston Park)       Date:  2016-01       Impact factor: 2.990

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.